a change of scene
Fundación Scherbovsky [Scherbovsky Foundation] is a medical specialties, clinical and pharmaceutical research center. It has been operating for more than 40 years in the province of Mendoza, Argentina, and now it is model foundation in pulmonology.

The Centro Médico Dr. Isaac Scherbovsky [Dr. Isaac Scherbovsky Medical Center] is a prestigious center located in Mendoza. It was originally founded by Dr. Isaac Scherbovsky many years ago, and then managed by his descendants, who have continuously devoted a great deal of effort to improve medical care and services provided.

After several years of conducting clinical research and always considering the latest breakthroughs in the area, the foundation decided to enlarge the center’s building by adapting its facilities to the current needs of the clinical research field.

For that purpose, Centro Médico Isaac Scherbovsky was thoroughly remodeled and, as a result, the building became more spacious, thus allowing streamlined work and, in particular, the possibility to offer high-quality services for patients who attend the center every day in search for a better quality of life.

Fundación Scherbovsky was established in December 2011, not only to conduct clinical research, but also to carry out disease prevention and diagnosis programs for the benefit of the community, focusing mainly on the most frequent respiratory diseases, such as asthma and COPD.

We believe that in this way, Fundación Scherbovsky partially compensates the community for all the support received for so many years. Nowadays, we are conducting Phase II, III & IV pharmacological research trials. During the last 7 years working in clinical research, we have achieved high recruitment levels with very low withdrawal or loss-to-follow-up rates, even for clinical trials that lasted for several months. This is due to the patient-specific follow-up and daily support we offer to help people enhance their quality of life.
In Fundación Scherbovsky, we have developed systematic educational and internal training programs which are run by physicians of this institution.

The research team has completed Clinical Research courses (GCP, quality, auditing, monitoring, sample handling, etc.) prior to joining the staff.

Recently, Fundación Scherbovsky together with the University of Mendoza and the CONICET has provided intensive clinical research training to all the personnel.

**STUDY COORDINATORS**

Coordinators are senior professionals who received academic education in clinical research, have good English language skills, and experience in electronic database management (EDC, RDC, TAG, ORACLE, FOSCO, IWRS, PERCEPTIVE, PREMIER, INFORM, among others).

**LABORATORY**

There is 1 biochemist and 1 lab technician with IATA certification and experience in handling and shipping samples.

In addition, the center's laboratory provides clinical services, for which purpose it counts with sufficient equipment to perform emergency lab tests when necessary.
• 6 doctor’s offices used for clinical research
• 2 bathrooms
• 2 monitoring rooms for research purposes with Wi-Fi internet access
• 1 pulmonary function laboratory with Medgraphics® equipment, prepared to perform spirometries, methacholine challenge tests and exercise induced asthma tests, assess the carbon monoxide diffusing capacity and the pulmonary volumes by nitrogen washout
• Clinical lab approved by the Ministry of Health of Mendoza
• Blood collection room
• 2 waiting rooms with armchairs, LCD TVs and cable television, DVD players and reading material
• Drugstore with restricted access and daily temperature controls
• Refrigerator and freezer for drug storage

• 12-lead electrocardiograph
• Scales and blood pressure monitors with calibration certificates
• Room temperature thermometers with min/max function
• Locked cupboards for each study, and restricted access to the study material and drug storage area
• Drug infusion room equipped with infusion armchairs, A/C, heating, cable television and reading material
• Automatic defibrillator with ambu bag and resuscitation cart
• Connectivity:
  - 4 telephone lines, 1 VoIP line, 1 direct fax line and 2 open lines
  - Direct fax
  - 2 input and output telephone lines
1. Study CQA1292314, Novartis

Recruitment period: 2 months
Number of patients enrolled: 5

2. Study ASBI307, Genexion
A phase IIb, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of SUN11031 for injection administered subcutaneously twice daily for 12 weeks to patients with chronic obstructive pulmonary disease, using formoterol (12 μg BID) as an active control. 2009.

Recruitment period: 1 month
Number of patients enrolled: 7

3. Protocol D9830C00008, AstraZeneca

Recruitment period: 4 months
Number of patients enrolled: 17

4. Protocol MKI113006, GlaxoSmithKline
A double-blind, placebo-controlled, randomized, double-blind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease. 2007.

Recruitment period: 2 months
Number of patients enrolled: 5

5. Protocol CQA149A2304, Novartis
A phase III, 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs. NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD). 2010-2012.

Recruitment period: 2 months
Number of patients enrolled: 7

6. Protocol CQA149A2303, Novartis

Recruitment period: 1 week
Number of patients enrolled: 5

7. Protocol D9130000008, Astro Zeneca

Recruitment period: 6 months
Number of patients enrolled: 19

8. Protocol HZC115247, GlaxoSmithKline
HZC115247: A 12-week study to evaluate the effect of fluticasone furoate (FF, GW856598c;Breatheasy® 150 μg o.d.) with salmeterol/fluticasone propionate (Seretide® Accuhaler® 50 μg/500 μg b.i.d.) in patients with moderate chronic obstructive pulmonary disease (COPD). 2011-2012.

Recruitment period: 4 months
Number of patients enrolled: 17

9. Protocol HZA115663, GlaxoSmithKline
A randomized, double-blind, parallel group, multi-center study of fluticasone furoate/vilanterol 100/25 mcg inhalation powder, and fluticasone furoate 100 mcg inhalation powder in the treatment of persistent asthma in adults and adolescents, 2013.

Recruitment period: 2 weeks
Number of patients enrolled: 30

10. Protocol HZA115588, GlaxoSmithKline
A randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. 2013.

Recruitment period: 2 weeks
Number of patients enrolled: 12
A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD. 2013.

Recruitment period: 15 days
Number of patients enrolled: 23

A placebo-controlled study to assess the long-term safety of once-daily QVA149 for 52 weeks in chronic obstructive pulmonary disease (COPD) patients with moderate to severe airflow limitation. 2013.

Recruitment period: 6 months
Number of patients enrolled: 23

A 52-week, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the effect of roflumilast 500 μg on exacerbation rate in subjects with chronic obstructive pulmonary disease (COPD) treated with a fixed-dose combination of long-acting beta agonist and inhaled corticosteroid (LABA/ICS). 2013.

Recruitment period: 11 months
Number of patients enrolled: 29

A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 Trials. 2013.

Recruitment period: N/A
Number of patients enrolled: 12

A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with chronic obstructive pulmonary disease (COPD) - Study 1. 2013.

Recruitment period: 20 days
Number of patients enrolled: 13

The center has databases with information about the patients.

The center has been subjected to several audits by the Independent Ethics Committees FEFYM, INAER and central audits by Novartis and GlaxoSmithKline. All of them showed excellent results.

The center counts with SOPs designed to provide the highest research quality, reduce time and errors, and to streamline work.

In order to download a PDF version of the SOPs used at Fundación Scherbovsky, please send an e-mail to pablo@fundacionscherbovsky.com indicating the reason for your request.
Fundación Scherbovsky
Dr. Pablo Saez Scherbovsky
Medical Director

Tel: +54 261 4307402 / 4306616 | Fax: +54 261 4379709 | Cell phone: +54 9 261 155942447
Email: pablo@fundacionscherbovsky.com | www.fundacionscherbovsky.com